A Rally Skeptic Says This Bullish Signal Is ‘Hard to Ignore’
(Bloomberg) -- Measures of stock-market breadth show that the damage done during the coronavirus-fueled slump is largely repaired, and that is a bullish signal for equities, according to an analysis from Sundial Capital Research.
McClellan Summation Indexes, which track the momentum of the underlying breadth of stocks moving in a benchmark, now show a “complete recovery,” Sundial's Jason Goepfert wrote in a note Wednesday. Such a move higher in the NYSE version has historically been a good sign for stock performance in coming months, even more so when the healing happens as quickly as it has here, he said.
“The rally has lasted long enough, and has been widespread enough, that longer-term breadth measures are recovering from their March devastation,” Goepfert wrote. Forward returns were “excellent” during periods in the past when the gauge swung to such a large degree within two months, he said.
Almost all major indexes tracked by Sundial now have positive McClellan Summation Indexes, according to the report. What's more, Goepfert found seven instances since 1962 when the NYSE's McClellan Summation Index recovered from below -1,000 to above +500 within 40 days -- and in every instance, the S&P 500 was higher two weeks out, as well as three months and one year afterward.
“What makes this recovery more impressive is how broad it is. Not just within the S&P 500 or even the NYSE, but across markets and across regions,” he wrote in the report. “It's hard to ignore this.”
By no means is Goepfert a perma bull. He has questioned multiple aspects of the market recovery in recent weeks, including the small group of stocks dominating gains and extreme bullishness by small options traders that he said is a bad sign for equity performance.
He even has a caveat on the McClellan Summation data: investors should be aware of anything that claims perfection, and ideally, he would look for “some kind of medium-term digestion to work off signs of shorter-term speculation and overbought conditions,” he concluded.
©2020 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.